Cargando…

Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study

BACKGROUND: FOLFIRINOX chemotherapy is the current Dutch standard of care for locally advanced (LAPC) and metastatic pancreatic cancer (PDAC) patients with good performance status. The objective of this study was to evaluate real-world response rates and survival in advanced PDAC and to assess condi...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Sijde, Fleur, van Dam, Jacob L., Groot Koerkamp, Bas, Haberkorn, Brigitte C. M., Homs, Marjolein Y. V., Mathijssen, Daniëlle, Besselink, Marc G., Wilmink, Johanna W., van Eijck, Casper H. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283068/ https://www.ncbi.nlm.nih.gov/pubmed/35847365 http://dx.doi.org/10.1155/2022/8549487

Ejemplares similares

Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients
por: van der Sijde, Fleur, et al.
Publicado: (2022)

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX
por: van der Sijde, Fleur, et al.
Publicado: (2021)

Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
por: van der Sijde, Fleur, et al.
Publicado: (2021)

Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Janssen, Quisette P., et al.
Publicado: (2021)

Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma
por: Farshadi, Elham Aida, et al.
Publicado: (2021)

Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients
por: van der Sijde, Fleur, et al.
Publicado: (2019)

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study
por: Suker, Mustafa, et al.
Publicado: (2018)

Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment
por: van der Sijde, Fleur, et al.
Publicado: (2021)

FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium
por: Janssen, Quisette P, et al.
Publicado: (2022)

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
por: van Dam, J. L., et al.
Publicado: (2023)

Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial)
por: Suker, Mustafa, et al.
Publicado: (2019)

The yield of chest computed tomography in patients with locally advanced pancreatic cancer
por: Suker, Mustafa, et al.
Publicado: (2020)

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
por: Janssen, Q. P., et al.
Publicado: (2021)

Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population‐based study
por: van der Geest, Lydia G. M., et al.
Publicado: (2018)

FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study
por: Rombouts, SJ, et al.
Publicado: (2016)

Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, Multicenter, Cohort Study
por: van ‘t Land, Freek R., et al.
Publicado: (2023)

Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study
por: van Veldhuisen, Eran, et al.
Publicado: (2022)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer
por: Rombouts, Steffi J., et al.
Publicado: (2016)

Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study
por: Pijnappel, Esther N., et al.
Publicado: (2022)

Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model
por: Latenstein, Anouk E. J., et al.
Publicado: (2020)

The value of serum amylase and drain fluid amylase to predict postoperative pancreatic fistula after pancreatoduodenectomy: a retrospective cohort study
por: van Dongen, Jelle C., et al.
Publicado: (2021)

Current evidence of nutritional therapy in pancreatoduodenectomy: Systematic review of randomized controlled trials
por: Takagi, Kosei, et al.
Publicado: (2019)

Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies
por: van Veldhuisen, Eran, et al.
Publicado: (2019)

Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries—Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients
por: de Koning, Willem, et al.
Publicado: (2023)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials
por: Doppenberg, Deesje, et al.
Publicado: (2023)

Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment
por: Vuijk, F. A., et al.
Publicado: (2020)

Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study
por: Latenstein, Anouk E. J., et al.
Publicado: (2020)

Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection
por: Vietsch, Eveline E., et al.
Publicado: (2019)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

RNA from stabilized whole blood enables more comprehensive immune gene expression profiling compared to RNA from peripheral blood mononuclear cells
por: van der Sijde, Fleur, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design
por: Doppenberg, D., et al.
Publicado: (2022)

Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
por: Chung, Moon Jae, et al.
Publicado: (2018)

Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design
por: Doppenberg, D., et al.
Publicado: (2023)

Cytopathological Analysis of Cyst Fluid Enhances Diagnostic Accuracy of Mucinous Pancreatic Cystic Neoplasms
por: Utomo, Wesley K., et al.
Publicado: (2015)

Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: van Mackelenbergh, Madelaine G., et al.
Publicado: (2019)

Treatment and Survival of Elderly Patients with Stage I–II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium
por: Groen, Jesse V., et al.
Publicado: (2020)

The bigger picture of shared decision making: A service design perspective using the care path of locally advanced pancreatic cancer as a case
por: Griffioen, Ingeborg P. M., et al.
Publicado: (2021)

The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The Rotterdam Study
por: Fest, Jesse, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fu0bnoiem1ouic39ju529ca2c8